166 related articles for article (PubMed ID: 18065960)
1. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome.
Chhibber V; Dresser K; Mahalingam M
Mod Pathol; 2008 Feb; 21(2):159-64. PubMed ID: 18065960
[TBL] [Abstract][Full Text] [Related]
2. Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome.
Machin P; Catasus L; Pons C; Muñoz J; Conde-Zurita JM; Balmaña J; Barnadas M; Martí RM; Prat J; Matias-Guiu X
J Cutan Pathol; 2002 Aug; 29(7):415-20. PubMed ID: 12139636
[TBL] [Abstract][Full Text] [Related]
3. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.
Mathiak M; Rütten A; Mangold E; Fischer HP; Ruzicka T; Friedl W; Propping P; Kruse R
Am J Surg Pathol; 2002 Mar; 26(3):338-43. PubMed ID: 11859205
[TBL] [Abstract][Full Text] [Related]
4. MSH-2 and MLH-1 protein expression in Muir Torre syndrome-related and sporadic sebaceous neoplasms.
Morales-Burgos A; Sánchez JL; Figueroa LD; De Jesús-Monge WE; Cruz-Correa MR; González-Keelan C; Nazario CM
P R Health Sci J; 2008 Dec; 27(4):322-7. PubMed ID: 19069357
[TBL] [Abstract][Full Text] [Related]
5. DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma.
Rajan Kd A; Burris C; Iliff N; Grant M; Eshleman JR; Eberhart CG
Am J Ophthalmol; 2014 Mar; 157(3):640-7.e1-2. PubMed ID: 24321472
[TBL] [Abstract][Full Text] [Related]
6. Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer.
Cesinaro AM; Ubiali A; Sighinolfi P; Trentini GP; Gentili F; Facchetti F
Am J Dermatopathol; 2007 Aug; 29(4):351-8. PubMed ID: 17667167
[TBL] [Abstract][Full Text] [Related]
7. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
[TBL] [Abstract][Full Text] [Related]
8. Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm.
Everett JN; Raymond VM; Dandapani M; Marvin M; Kohlmann W; Chittenden A; Koeppe E; Gustafson SL; Else T; Fullen DR; Johnson TM; Syngal S; Gruber SB; Stoffel EM
JAMA Dermatol; 2014 Dec; 150(12):1315-21. PubMed ID: 25006859
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
[TBL] [Abstract][Full Text] [Related]
10. Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series.
Cohen PR; Kurzrock R
Cureus; 2023 Jan; 15(1):e33975. PubMed ID: 36824550
[TBL] [Abstract][Full Text] [Related]
11. [Muir-Torre syndrome and Turcot syndrome].
Velter C; Caussade P; Fricker JP; Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
[TBL] [Abstract][Full Text] [Related]
12. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy.
Ponti G; Meschieri A; Pollio A; Ruini C; Manfredini M; Longo C; Mandel VD; Ciardo S; Tomasi A; Giannetti L; Pellacani G
J Oral Pathol Med; 2015 Aug; 44(7):552-7. PubMed ID: 25213213
[TBL] [Abstract][Full Text] [Related]
13. Muir-Torre syndrome.
Navi D; Wadhera A; Fung MA; Fazel N
Dermatol Online J; 2006 Sep; 12(5):4. PubMed ID: 16962019
[TBL] [Abstract][Full Text] [Related]
14. Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias.
Kruse R; Rütten A; Schweiger N; Jakob E; Mathiak M; Propping P; Mangold E; Bisceglia M; Ruzicka T
J Invest Dermatol; 2003 May; 120(5):858-64. PubMed ID: 12713593
[TBL] [Abstract][Full Text] [Related]
15. The role of immunohistochemistry in the Muir-Torre Syndrome.
Oliveira CM; Campos JG; Maia MR; Lobo LE; Valle FF
An Bras Dermatol; 2015; 90(3 Suppl 1):168-70. PubMed ID: 26312706
[TBL] [Abstract][Full Text] [Related]
16. An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome.
Nguyen CV; Gaddis KJ; Stephens MR; Seykora JT; Chu EY
JAMA Dermatol; 2020 Jun; 156(6):676-680. PubMed ID: 32267475
[TBL] [Abstract][Full Text] [Related]
17. Retroperitoneal undifferentiated pleomorphic sarcoma having microsatellite instability associated with Muir-Torre syndrome: case report and review of literature.
Lee N; Luthra R; Lopez-Terrada D; Wang WL; Lazar AJ
J Cutan Pathol; 2013 Aug; 40(8):730-3. PubMed ID: 23672746
[TBL] [Abstract][Full Text] [Related]
18. Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study.
Rütten A; Burgdorf W; Hügel H; Kutzner H; Hosseiny-Malayeri HR; Friedl W; Propping P; Kruse R
Am J Dermatopathol; 1999 Oct; 21(5):405-13. PubMed ID: 10535567
[TBL] [Abstract][Full Text] [Related]
19. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
20. [Muir-Torre syndrome and familial colorectal cancer: 2 families with molecular genetic analysis].
Doré MX; Dieumegard B; Grandjouan S; Avril MF; Martinet C; Ducreux M; Lasser P; Bressac-de Paillerets B
Ann Dermatol Venereol; 1999; 126(8-9):582-6. PubMed ID: 10530344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
